Inflammatory predictors of mortality in the Scandinavian Simvastatin Survival Study

Clinical Cardiology

Volumn 25, Issue 10, 2002, Pages 461-466

  Crea, Filippo ^a   Monaco, Claudia ^b   Lanza, Gaetano A ^a   Maggi, Elena ^a   Ginnetti, Francesca ^a   Cianflone, Domenico ^a   Niccoli, Giampaolo ^a   Cook, Thomas ^a   Bellomo, Giorgio ^a   Kjekshus, John ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

Coronary disease; Infection; Inflammation; Lipids; Mortality

Indexed keywords

ANTIBODY; LOW DENSITY LIPOPROTEIN; PLACEBO; SIMVASTATIN;

ADULT; AGED; ANTIBODY DETECTION; ARTICLE; BACTERIAL INFECTION; BLOOD SAMPLING; CHLAMYDOPHILA PNEUMONIAE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFECT; FEMALE; FOLLOW UP; HELICOBACTER PYLORI; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXIDATION; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RANDOMIZATION; RISK ASSESSMENT; SCANDINAVIA; SERODIAGNOSIS; SURVIVAL;

AGED; ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SCANDINAVIA; SEROEPIDEMIOLOGIC STUDIES; SIMVASTATIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 0036792290     PISSN: 01609289     EISSN: None     Source Type: Journal    
DOI: 10.1002/clc.4960251005     Document Type: Article

References (33)

1. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336(14):973-979
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97(5):425-428
3. Kuller LH, Tracy RP, Shaten J, Meilahn EN: Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;144(6):537-547
4. Tracy RP, Lemaitre RN, Psaty BM, Ives DG, Evans RW, Cushman M, Meilahn EN, Kuller LH: Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997;17(6):1121-1127
5. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC: Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995;332(10):635-641
6. Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB: Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349(9050):462-466
7. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994;331(7):417-424
8. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, McFarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333(20):1301-1307
9. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383-1389
10. Ridker PM, Rifai N, Pfeifer MA, Sacks FM, Moyé LA, Goldman S, Fiacker GC, Braunwald E: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98(9):839-844
11. Cuthbert JA, Lipsky PE: Sterol metabolism and lymphocyte responsiveness: Inhibition of endogenous sterol synthesis prevents mitogen-induced human T cell proliferation. J Immunol 1981:126(6):2093-2099
12. Cutts JL, Bankhurst AD: Suppression of lymphoid cell function in vitro by inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by lovastatin. Int J Immunopharmacol 1989;11(8):863-869
13. Weber C, Erl W, Weber KS, Weber PC: HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol 1997;30(5):1212-1217
14. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manniken V, Manttari M, Frick MH, Huttunen JK: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992:116(4):273-278
15. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96(2):404-407
16. Gurfinkel E, Bozovich G, Daroca A, Beck E, Maumer B: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350(9075):404-407
17. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, Levy J, Blakeston C, Seymour CA, Camm AJ, Northfield TC: Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. Br Med J 1995;311(7007):711-714
18. Mendall MA, Goggin PM, Molineaux N, Levi J, Toosy T, Strachan D, Camm AJ, Northfield TC: Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994;71(5):437-439
19. Maggi E, Perani G, Falaschi F, Frattoni A, Martignoni A, Finardi G, Stefano PL, Simeone F, Paolini G, DeVecchi E, Grossi A, Bettomo G: Autoantibodies against oxidised low density lipoproteins in patients with coronary disease. Presse Med 1994;23(25):1158-1162
20. Maggi E, Finardi G, Poli M, Bollati P, Filipponi M, Stefano PL, Paolini G, Grossi A, Clot P, Albano E: Specificity of autoantibodies against oxidized LDL as an additional marker for atherosclerotic risk. Coron Artery Dis 1993;4(12):1119-1122
21. Maggi E, Marchesi E, Ravetta V, Martignoni A, Finardi G, Bellomo G: Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: A biochemical signature of an enhanced in vivo low-density lipoprotein oxidation. J Hypertens 1995;13(1):129-138
22. Seccia M, Albano E, Maggi E, Bellomo G: Circulating autoantibodies recognizing peroxidase-oxidized low density lipoprotein. Evidence for new antigenic epitopes formed in vivo independently from lipid peroxidation. Arterioscler Thromb Vasc Biol 1997;17(1):134-140
23. Anzai T, Yoshikawa T, Shiraki H, Asakura, Y, Akaishi M, Mitamura H, Ogawa S: C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation 1997;96(3):778-784
24. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G: Dual control of C-reactive protein gene expression by interleukin-1 and interleukin-6. Embo J 1989;8(12):3773-3779
25. Yap SH, Moshage HJ, Hazenberg BP, Roelofs HM, Bitzet J, Limburg PL, Aarden LA, van Ritswijk MH: Tumor necrosis factor (TNF) inhibits interleukin (IL)-1 and/or IL-6 stimulated synthesis of C-reactive protein (CRP) and serum amyloid A (SAA) in primary cultures of human hepatocytes. Biochim Biophys Acta 1991;1091(3):405-408
26. Bevilacqua MP, Gimbrone MA Jr: Inducible endothelial functions in inflammation and coagulation. Semin Thromb Hemost 1987;13(4):425-433
27. Lee RT, Libby P: The unstable atheroma. Arrerioscler Thromb Vasc Biol 1997;17(10):1859-1867
28. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995;91(4):941-947
29. Ross RM, Young JA: Clinical and necropsy finding in rupture of the myocardium: A review of forty-three cases. Scott Med J 1963;8:222-226
30. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH: Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999;99(9):1161-1164
31. Monaco C, Crea F, Niccoli G, Summaria F, Cianflone D, Bordone R, Bellomo G, Maseri A: Autoantibodies against oxidized low density lipoproteins in patients with stable angina, unstable angina or peripheral vascular disease: Pathophysiological implications. Eur Heart J 2001;22(17):1572-1577
32. The Cholesterol and Recurrent Events (CARE) Investigators: Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation 1999;20:100(3):230-235
33. Ridker PM, Rifai N, Clearfield M, Downs J, Weis SE, Miles JS, Gotto A: Measurements of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344(26):1959-1965